Rhabdomyolysis Induced by Isoniazid in a Patient with Rheumatoid Arthritis and End-stage Renal Disease: A Case Report and Review of the Literature

Intern Med. 2018 Aug 15;57(16):2413-2416. doi: 10.2169/internalmedicine.0463-17. Epub 2018 Mar 9.

Abstract

A 76-year-old man complicated with end-stage renal disease had latent tuberculosis infection (LTBI), and isoniazid (INH) 300 mg daily was started to prevent reactivation of LTBI before using biologic agents for rheumatoid arthritis. On the 8th day after administration of INH, he presented with a fever, petechiae, and myalgia. Serological studies revealed elevated myogenic enzymes and creatinine level. Based on the exclusion of other etiologies, rapid improvement with cessation of INH, and the recurrence of the fever and myalgia with re-administration of a reduced dose of INH, we diagnosed him with INH-induced rhabdomyolysis. Physicians should be aware of rhabdomyolysis induced by INH at a therapeutic dose as an infrequent but potentially fatal adverse drug reaction.

Keywords: end-stage renal disease; isoniazid; latent tuberculosis infection; rhabdomyolysis; rheumatoid arthritis.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged
  • Anti-Bacterial Agents / adverse effects*
  • Anti-Bacterial Agents / therapeutic use*
  • Antitubercular Agents / adverse effects*
  • Antitubercular Agents / therapeutic use
  • Arthritis, Rheumatoid / complications
  • Arthritis, Rheumatoid / drug therapy*
  • Humans
  • Isoniazid / adverse effects*
  • Isoniazid / therapeutic use
  • Kidney Failure, Chronic / complications
  • Latent Tuberculosis / drug therapy*
  • Male
  • Rhabdomyolysis / drug therapy*
  • Rhabdomyolysis / etiology
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Antitubercular Agents
  • Isoniazid